Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Stock Exchange of Hong Kong  >  Wuxi Biologics Cayman Inc    2269   KYG970081090

WUXI BIOLOGICS CAYMAN INC

(2269)
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Wuxi Biologics Cayman : CANbridge Pharmaceuticals expands partnership with Wuxi Biologics

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:40am EDT

Chinas CANbridge Pharmaceuticals has expanded its alliance with WuXi Biologics for the discovery, development and commercialisation of four additional drug candidates to potentially treat rare genetic chronic diseases.

As per the agreement, CANbridge holds exclusive regional or global rights to these drug candidates. In turn, WuXi Biologics will receive upfront and milestone payments as well as royalties.

WuXi Biologics will act as the exclusive clinical and primary commercial supplier for all the programmes.

CANbridge Pharmaceuticals founder, chairman and CEO James Xue said: With this expansion of our partnership with WuXi Biologics, CANbridge continues to broaden our presence in rare disease, with a goal of bringing to the market treatments that are developed in China.

These four new drug candidates target important rare disease indications for which there are either no available treatments in China or treatments with poor outcomes.

These candidates are next-generation therapies directed at medically-validated biological targets.

CANbridge and WuXi Biologics initially partnered in October last year to develop and commercialise a range of biotherapeutics targeting rare diseases.

The partnership combines CANbridges clinical, regulatory and commercial expertise with WuXis drug discovery, development and manufacturing capabilities.

First investigational New Drug (IND) application for the lead rare disease candidate from this programme is expected to be submitted later this year in China.

In the future, the partners also intend to develop the therapeutics on a global basis.

WuXi Biologics CEO Chris Chen added: This expanding partnership further validates our world-class technology platforms and capabilities.

Improving the availability of biologics for rare disease aligns with our mission of accelerating and transforming how biologics are developed and manufactured worldwide.

(c) International 2006-2019, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WUXI BIOLOGICS CAYMAN INC
06/11WUXI BIOLOGICS CAYMAN : Jacobs Wins Contract to Provide Construction Services fo..
AQ
05/25WUXI BIOLOGICS CAYMAN : in $3bn deal to manufacture 'first of its kind' vaccine
AQ
05/22WUXI BIOLOGICS CAYMAN : Signed Letter of Intent for Long-Term Vaccine Manufactur..
AQ
05/17WUXI BIOLOGICS CAYMAN : Commenced Construction of a 48,000 L Integrated Manufact..
AQ
05/17WUXI BIOLOGICS CAYMAN : to build 1.3m-sq-ft manufacturing centre
AQ
04/17WUXI BIOLOGICS CAYMAN : I-Mab Biopharma and WuXi Biologics Announce Long-term St..
AQ
04/10WUXI BIOLOGICS CAYMAN : and NBE-Therapeutics Announce Comprehensive ADC Developm..
AQ
03/27WUXI BIOLOGICS CAYMAN : Receives "Asia`s Best CMO of 2018" Award from IMAPAC
AQ
03/23WUXI BIOLOGICS CAYMAN : PharmaTech subsidiaries hit regulatory and manufacturing..
AQ
03/08Viral Clearance Market by Method, Application, End User - Global Analysis & F..
AQ
More news
Financials (HKD)
Sales 2019 4 520 M
EBIT 2019 1 235 M
Net income 2019 1 156 M
Finance 2019 2 384 M
Yield 2019 -
P/E ratio 2019 80,30
P/E ratio 2020 53,11
EV / Sales 2019 19,3x
EV / Sales 2020 12,6x
Capitalization 89 737 M
Chart WUXI BIOLOGICS CAYMAN INC
Duration : Period :
Wuxi Biologics Cayman Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 98,2  HKD
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Zhi Sheng Chen Chief Executive Officer & Executive Director
Ge Li Non-Executive Chairman
Shao Hua Lu-Wong Chief Financial Officer
Weichang Zhou Executive Director, Chief Technology Officer & SVP
Edward Hu Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
WUXI BIOLOGICS CAYMAN INC11 550
CSL LIMITED14.18%64 329
BIOGEN-22.98%43 310
ALEXION PHARMACEUTICALS21.13%25 574
SAMSUNG BIOLOGICS CO LTD--.--%16 821
GRIFOLS6.11%16 048